Comparative effectiveness and cost-effectiveness of treat-to-target versus benefit-based tailored treatment of type 2 diabetes in low-income and middle-income countries: a modelling analysis

The Lancet Diabetes and Endocrinology

Volumn 4, Issue 11, 2016, Pages 922-932

  Basu, Sanjay ^a,b   Shankar, Vishnu ^a   Yudkin, John S ^c  

^a STANFORD UNIVERSITY   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; GLUCOSE; HEMOGLOBIN A1C; INSULIN; ISOPHANE INSULIN; LOW DENSITY LIPOPROTEIN; METFORMIN; SULFONYLUREA DERIVATIVE;

ADULT; AGE; AGED; ARTICLE; BENEFIT BASED TAILORED TREATMENT STRATEGY; BLINDNESS; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; CHINA; COHORT ANALYSIS; COMPARATIVE EFFECTIVENESS; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DIABETIC FOOT; DIET RESTRICTION; END STAGE RENAL DISEASE; FEMALE; GHANA; GLUCOSE BLOOD LEVEL; HEART INFARCTION; HUMAN; INDIA; LOW INCOME COUNTRY; MAJOR CLINICAL STUDY; MALE; METHODOLOGY; MEXICO; MIDDLE INCOME COUNTRY; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; SEX DIFFERENCE; SOUTH AFRICA; TREAT TO TARGET STRATEGY; COMBINATION DRUG THERAPY; COMPARATIVE STUDY; COST BENEFIT ANALYSIS; DEVELOPING COUNTRY; ECONOMICS; MIDDLE AGED; THEORETICAL MODEL; YOUNG ADULT;

ADULT; AGED; COST-BENEFIT ANALYSIS; DEVELOPING COUNTRIES; DIABETES MELLITUS, TYPE 2; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; MALE; MIDDLE AGED; MODELS, THEORETICAL; YOUNG ADULT;

EID: 84994131485     PISSN: 22138587     EISSN: 22138595     Source Type: Journal    
DOI: 10.1016/S2213-8587(16)30270-4     Document Type: Article

References (44)

1. 1 Global Burden of Disease Study 2013 Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 301 acute and chronic diseases and injuries in 188 countries, 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet 386 (2015), 743–800.
2. 2 Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group. BMJ 317 (1998), 703–713.
3. 3 Zoungas, S, Chalmers, J, Neal, B, et al. Follow-up of blood-pressure lowering and glucose control in type 2 diabetes. N Engl J Med 371 (2014), 1392–1406.
4. 4 Duckworth, W, Abraira, C, Moritz, T, et al. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med 360 (2009), 129–139.
5. 5 American Diabetes Association. Standards of medical care in diabetes—2014. Diabetes Care 37 (2014), S14–S80.
6. 6 Goff, DC, Lloyd-Jones, DM, Bennett, G, et al. 2013 ACC/AHA guideline on the assessment of cardiovascular risk. J Am Coll Cardiol 63 (2014), 2935–2959.
7. 7 Muntner, P, Colantonio, LD, Cushman, M, et al. Validation of the atherosclerotic cardiovascular disease Pooled Cohort risk equations. JAMA 311 (2014), 1406–1415.
8. 8 Pandya, A, Sy, S, Cho, S, Weinstein, MC, Gaziano, TA, Cost-effectiveness of 10-year risk thresholds for initiation of statin therapy for primary prevention of cardiovascular disease. JAMA 314 (2015), 142–150.
9. 9 Eddy, DM, Adler, J, Patterson, B, Lucas, D, Smith, KA, Morris, M, Individualized guidelines: the potential for increasing quality and reducing costs. Ann Intern Med, 154, 2011, 627.
10. 10 Sussman, J, Vijan, S, Hayward, R, Using benefit-based tailored treatment to improve the use of antihypertensive medications. Circulation 128 (2013), 2309–2317.
11. 11 SPRINT Research Group, Wright, JT, Williamson, JD, et al. A randomized trial of intensive versus standard blood-pressure control. N Engl J Med 373 (2015), 2103–2116.
12. 12 Lonn, EM, Bosch, J, López-Jaramillo, P, et al. Blood-pressure lowering in intermediate-risk persons without cardiovascular disease. N Engl J Med 374 (2016), 2009–2020.
13. 13 The Blood Pressure Lowering Treatment Trialists' Collaboration. Blood pressure-lowering treatment based on cardiovascular risk: a meta-analysis of individual patient data. Lancet 384 (2014), 591–598.
14. 14 The Action to Control Cardiovascular Risk in Diabetes Study Group. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 358 (2008), 2545–2559.
15. 15 Boussageon, R, Bejan-Angoulvant, T, Saadatian-Elahi, M, et al. Effect of intensive glucose lowering treatment on all cause mortality, cardiovascular death, and microvascular events in type 2 diabetes: meta-analysis of randomised controlled trials. BMJ, 343, 2011, d4169.
16. 16 Stratton, IM, Cull, CA, Adler, AI, Matthews, DR, Neil, HAW, Holman, RR, Additive effects of glycaemia and blood pressure exposure on risk of complications in type 2 diabetes: a prospective observational study (UKPDS 75). Diabetologia 49 (2006), 1761–1769.
17. 17 Basu, S, Bendavid, E, Sood, N, Health and economic implications of national treatment coverage for cardiovascular disease in india cost-effectiveness analysis. Circ Cardiovasc Qual Outcomes 8 (2015), 541–551.
18. 18 World Bank. World development indicators 2014, 2015, World Bank Publications, Washington, DC.
19. 19 UN. World population prospects: the 2012 revision, 2013, United Nations, Geneva.
20. 20 International Diabetes Federation. Diabetes atlas, 2015, International Diabetes Federation, Brussels.
21. 21 Kowal, P, Chatterji, S, Naidoo, N, et al. Data resource profile: the World Health Organization Study on global AGEing and adult health (SAGE). Int J Epidemiol 41 (2012), 1639–1649.
22. 22 Public Health England. Adult obesity and type 2 diabetes. London: Public Health England. https://www.gov.uk/government/publications/adult-obesity-and-type-2-diabetes (accessed Aug 23, 2016).
23. 23 Menke, A, Casagrande, S, Geiss, L, Cowie, CC, Prevalence of and trends in diabetes among adults in the United States, 1988–2012. JAMA 314 (2015), 1021–1029.
24. 24 Guariguata, L, Whiting, DR, Hambleton, I, Beagley, J, Linnenkamp, U, Shaw, JE, Global estimates of diabetes prevalence for 2013 and projections for 2035. Diabetes Res Clin Pract 103 (2014), 137–149.
25. 25 Hayes, AJ, Leal, J, Gray, AM, Holman, RR, Clarke, PM, UKPDS outcomes model 2: a new version of a model to simulate lifetime health outcomes of patients with type 2 diabetes mellitus using data from the 30 year United Kingdom Prospective Diabetes Study: UKPDS 82. Diabetologia 56 (2013), 1925–1933.
26. 26 Clarke, P, Constructing diabetes model from individual level data, 2014, Stanford University, Palo Alto.
27. 27 American Diabetes Association. Dyslipidemia management in adults with diabetes. Diabetes Care 27 (2004), s68–s71.
28. 28 WHO. Package of essential noncommunicable (pen) disease interventions for primary health care in low-resource settings, 2013, World Health Organization, Geneva.
29. 29 Law, MR, Wald, NJ, Morris, JK, Jordan, RE, Value of low dose combination treatment with blood pressure lowering drugs: analysis of 354 randomised trials. BMJ, 326, 2003, 1427.
30. 30 Law, MR, Wald, NJ, Rudnicka, AR, Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke: systematic review and meta-analysis. BMJ, 326, 2003, 1423.
31. 31 Lewington, S, Clarke, R, Qizilbash, N, Peto, R, Collins, R, Prospective Studies Collaboration. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet 360 (2002), 1903–1913.
32. 32 Cholesterol Treatment Trialists' (CTT) Collaborators. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90 056 participants in 14 randomised trials of statins. Lancet 366 (2005), 1267–1278.
33. 33 Hemmingsen, B, Lund, SS, Gluud, C, et al. Targeting intensive glycaemic control versus targeting conventional glycaemic control for type 2 diabetes mellitus. Cochrane Database Syst Rev, 6, 2011 CD008143.
34. 34 Hayward, RA, Krumholz, HM, Zulman, DM, Timbie, JW, Vijan, S, Optimizing statin treatment for primary prevention of coronary artery disease. Ann Intern Med 152 (2010), 69–77.
35. 35 Basu, S, Yudkin, JS, Sussman, JB, Millett, C, Hayward, RA, Alternative strategies to achieve cardiovascular mortality goals in China and India: a microsimulation of target- versus risk-based blood pressure treatment. Circulation 133 (2016), 840–848.
36. 36 Mendis, S, Fukino, K, Cameron, A, et al. The availability and affordability of selected essential medicines for chronic diseases in six low- and middle-income countries. Bull World Health Organ 85 (2007), 279–288.
37. 37 WHO. WHO model list of essential medicines, 19th edn., 2015, World Health Organization, Geneva.
38. 38 WHO. Choosing interventions that are cost effective (WHO-CHOICE), 2010, World Health Organization, Geneva.
39. 39 Husereau, D, Drummond, M, Petrou, S, et al. Consolidated health economic evaluation reporting standards (CHEERS)—explanation and elaboration: a report of the ISPOR Health Economic Evaluation Publication Guidelines Good Reporting Practices Task Force. Value Health 16 (2013), 231–250.
40. 40 Danaei, G, Finucane, MM, Lu, Y, et al. National, regional, and global trends in fasting plasma glucose and diabetes prevalence since 1980: systematic analysis of health examination surveys and epidemiological studies with 370 country-years and 2·7 million participants. Lancet 378 (2011), 31–40.
41. 41 Salomon, JA, Vos, T, Hogan, DR, et al. Common values in assessing health outcomes from disease and injury: disability weights measurement study for the Global Burden of Disease Study 2010. Lancet 380 (2013), 2129–2143.
42. 42 Management Sciences for Health. International drug price indicator guide, 2015, Management Sciences for Health, Cambridge, MA http://www.msh.org/sites/msh.org/files/international-drug-price-indicator-guide.pdf (accessed Jan 28, 2015).
43. 43 Beran, D, Ewen, M, Laing, R, Constraints and challenges in access to insulin: a global perspective. Lancet Diabetes Endocrinol 4 (2016), 275–285.
44. 44 Pandya, A, Sy, S, Cho, S, Weinstein, MC, Gaziano, TA, Cost-effectiveness of 10-year risk thresholds for initiation of statin therapy for primary prevention of cardiovascular disease. JAMA 314 (2015), 142–150.